导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.41% | 1627/4773 |
| 近一周 | -1.79% | 2828/5465 |
| 近一月 | -2.87% | 1976/5421 |
| 近一季 | -5.41% | 2061/5231 |
| 近半年 | 1.28% | 1182/4920 |
| 近一年 | 5.67% | 1677/4394 |
| 近两年 | 49.11% | 1523/2954 |
| 近三年 | 31.33% | 1043/2253 |
| 成立以来 | 48.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.51% 2808/4961 |
16.54% 1556/5312 |
- - |
- - |
| 2025 | 19.30% 2232/4813 |
-0.79% 2410/3635 |
2.68% 1429/4076 |
16.99% 2569/4524 |
0.10% 2219/4813 |
| 2024 | 14.44% 1047/3463 |
3.56% 545/2808 |
-1.05% 904/3014 |
15.08% 1818/3129 |
-2.95% 2216/3463 |
| 2023 | -7.94% 965/2656 |
4.26% 1005/2280 |
-4.37% 1152/2385 |
-0.91% 465/2515 |
-6.82% 1936/2655 |
| 2022 | -21.37% 1029/2207 |
-14.61% 979/1919 |
6.97% 564/2016 |
-13.98% 1004/2113 |
0.06% 1545/2208 |
| 2021 | 4.97% 559/1822 |
1.65% 248/1255 |
7.43% 684/1330 |
-3.36% 633/1466 |
-0.53% 1245/1822 |
| 2020 | 37.54% 379/1250 |
-8.96% 643/1028 |
14.93% 530/1067 |
14.42% 276/1164 |
14.90% 243/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 天弘沪深300指数增强发起C VS. 长安沪深300非周期A(740101) |